Get started
Author

Fabio Mirabella

Observed names: F Mirabella, F. Mirabella
ORCID: 0000-0003-3785-6868
Observed ORCID: 0000-0003-3785-6868
OpenAlex ID: A5033467802
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
2015 · Brian A. Walker, Eileen M. Boyle, et al. · Journal of Clinical Oncology · 565
PDF
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
2013 · B A Walker, C P Wardell, et al. · Leukemia · 283
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma
2013 · Martin F. Kaiser, David C. Johnson, et al. · Blood · 167
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
2012 · A S Moore, A Faisal, et al. · Leukemia · 117
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
2017 · C Pawlyn, M D Bright, et al. · Blood Cancer Journal · 109
PDF
Improved risk stratification in myeloma using a micro RNA ‐based classifier
2013 · Ping Wu, Luca Agnelli, et al. · British Journal of Haematology · 59
HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target
2018 · Jacqueline H.L. Fok, Somaieh Hedayat, et al. · Clinical Cancer Research · 55
MMSET is the key molecular target in t(4;14) myeloma
2013 · F Mirabella, P Wu, et al. · Blood Cancer Journal · 47
PDF
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
2018 · Molly Went, Amit Sud, et al. · Blood Cancer Journal · 43
PDF
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression
2016 · Ni Li, David C. Johnson, et al. · Nature Communications · 35
PDF
The Human IL-3/Granulocyte-Macrophage Colony-Stimulating Factor Locus Is Epigenetically Silent in Immature Thymocytes and Is Progressively Activated during T Cell Development
2010 · Fabio Mirabella, Euan W Baxter, et al. · The Journal of Immunology · 34
PDF
A Conserved Insulator That Recruits CTCF and Cohesin Exists between the Closely Related but Divergently Regulated Interleukin-3 and Granulocyte-Macrophage Colony-Stimulating Factor Genes
2009 · Sarion R. Bowers, Fabio Mirabella, et al. · Molecular and Cellular Biology · 33
Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress
2013 · Lei Zhang, Jacqueline J.L. Fok, et al. · Cancer Letters · 32
PDF
Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application
2013 · L I Aronson, E L Davenport, et al. · Leukemia · 25
PDF
The Inducible Tissue-Specific Expression of the Human IL-3/GM-CSF Locus Is Controlled by a Complex Array of Developmentally Regulated Enhancers
2012 · Euan W Baxter, Fabio Mirabella, et al. · The Journal of Immunology · 14
PDF
A Novel Functional Role for MMSET in RNA Processing Based on the Link Between the REIIBP Isoform and Its Interaction with the SMN Complex
2014 · Fabio Mirabella, Alexander Murison, et al. · PLoS ONE · 13
PDF
The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma
2017 · Karen Menezes, Grace Aram, et al. · Blood · 5
Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling
2016 · Amy L Sherborne, Dil B Begum, et al. · Blood · 3
Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features
2016 · Charlotte Pawlyn, Michael Bright, et al. · Blood · 2
DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome
2016 · David C Johnson, Dil B Begum, et al. · Blood · 1
Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients
2014 · Eileen M Boyle, Brian A Walker, et al. · Blood · 1
Integrating Molecular Genetic and Gene Expression Profiling Allows Stratification of Ultra-High Risk Myeloma
2017 · Amy Sherborne, Dil Begum, et al. · Clinical Lymphoma Myeloma & Leukemia
EZH2 overexpression in myeloma patients shortens survival and in-vitro data supports a potential new targeted treatment strategy
2015 · C. Pawlyn, M. Kaiser, et al. · Clinical Lymphoma Myeloma & Leukemia
Abstract 3379: HSF1: Essential for myeloma cell survival and a promising therapeutic target
2015 · Jacqueline H L Fok, Somaieh Hedayat, et al. · Cancer Research
Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients
2014 · Eileen M. Boyle, Brian A. Walker, et al. · Newcastle University ePrints (Newcastle Univesity)
Works count: 31
Citation count: 1,643
H-index: 14
I10-index: 16
Year
Topic
Type